跳至主要内容
临床试验/NCT00681772
NCT00681772已完成4 期

Open-label, Multi-centre, Study to Investigate the Safety, Tolerability and Efficacy of Flexible Doses of Vardenafil Given on Demand in Males With Erectile Dysfunction

Bayer0 个研究点目标入组 333 人开始时间: 2003年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Bayer
入组人数
333
主要终点
International Index of Erectile Function - Erectile Function Domain

研究概览

简要总结

Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. An ideal treatment option should be effective and reliable, have minimal side effects, be simple to use and affordable. The aim of this study was to investigate safety, tolerability and efficacy of vardenafil following a flexible dose treatment schedule in subjects with varying aetiology.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Men >/= 18 years of age,
  • ED 6 months or longer
  • Stable sexual relationship for > 6 month.

排除标准

  • Primary hypoactive sexual desire
  • History of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month
  • Nitrate therapy
  • Other exclusion criteria apply according to the Summary of Product Characteristics

研究组 & 干预措施

Arm 1

Experimental

干预措施: Levitra (Vardenafil, BAY38-9456) (Drug)

结局指标

主要结局

International Index of Erectile Function - Erectile Function Domain

时间窗: 12 weeks

次要结局

  • Sexual Encounter Profile Question 2 and 3(12 weeks)
  • Global Assessment Question(12 weeks)
  • Other diary based variables(12 weeks)
  • Safety and tolerability(12 weeks)

研究者

发起方
Bayer
申办方类型
Industry

相似试验